HINDHealthcare · BiotechnologyHIND Stock Forecast: Vyome Holdings, Inc. Price Predictions for 2026-2027
The 2 Wall Street analysts covering Vyome Holdings, Inc. hold a median 12-month price target of $12 — +443.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 1 Aug 2026 — in the lower half.
HIND stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Vyome Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (90): Smaller than most of the companies we track.
Momentum (12): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Vyome Holdings, Inc. — and when they’d sell — is the membership.
HIND stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on HIND, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +443.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Oct 2025 | Maxim Group | Assumes | Buy | $15 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
HIND analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Vyome Holdings, Inc. (HIND) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.4×
- Price / sales
- 97.2×
- Price / book
- 2.2×
- EV / EBITDA
- −2.0×
Cheaper than 79% of US stocks
Cheaper than 4% of US stocks
Cheaper than 43% of US stocks
Cheaper than 72% of US stocks
- Revenue growth (YoY)
- −84.1%
- Earnings growth (YoY)
- −48.6%
- Gross margin
- 52.7%
- Operating margin
- −3576.8%
- Net margin
- 68.4%
Higher than 3% of US stocks
Higher than 10% of US stocks
Higher than 67% of US stocks
Higher than 3% of US stocks
Higher than 97% of US stocks
- Return on equity
- −665.6%
- Return on assets
- −39.5%
- Dividend yield
- —
Higher than 2% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
HIND vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HIND appears on the weeks it earns a place.
Frequently asked questions about HIND stock
What is the HIND stock price forecast for 2026-2027?
The 2 Wall Street analysts covering Vyome Holdings, Inc. have a median 12-month price target of $12, with estimates ranging from $8 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is HIND stock a buy right now?
Of the 2 analysts covering Vyome Holdings, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vyome Holdings, Inc. 42 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank HIND?
As at 1 Aug 2026, Vyome Holdings, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).
Will HIND stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +443.7% from the last close, and Ticker Nerd's factor model ranks Vyome Holdings, Inc. 42 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the HIND stock forecast for 2030?
No analyst covering Vyome Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HIND are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $15 over the next 12 months.
What does Vyome Holdings, Inc. do?
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
About Vyome Holdings, Inc.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
CEO Mr. Venkateswarlu Nelabhotla M.B.A. · 9 employees · United States · https://www.vyometx.com